Related Experiment Videos
Positron emission tomography imaging-directed stereotactic neurosurgery.
R J Maciunas1, R M Kessler, C Maurer
1Department of Neurological Surgery, Vanderbilt University Medical Center, Nashville, Tenn.
Stereotactic and Functional Neurosurgery
|January 1, 1992
Summary
Positron Emission Tomography (PET) with fluorodeoxyglucose (FDG) enhances stereotactic biopsies for brain tumors. PET-FDG imaging guides biopsies when CT and MRI are inconclusive, improving diagnostic accuracy.
Area of Science:
- Neurosurgery
- Medical Imaging
- Oncology
Background:
- Stereotactic biopsies are crucial for diagnosing intracranial mass lesions.
- Accurate sampling of representative tumor regions is essential for diagnostic yield.
- Current imaging modalities like CT and MRI may have limitations in characterizing metabolically active areas.
Purpose of the Study:
- To evaluate the utility of Positron Emission Tomography (PET) with fluorodeoxyglucose (FDG) in improving the diagnostic yield of stereotactic biopsies.
- To assess if PET-FDG imaging can provide additional localization information beyond CT and MRI for intracranial mass lesions.
Main Methods:
- Ten selected stereotactic biopsies of intracranial mass lesions were performed.
- PET scans were acquired using a Siemens CTI system.
- The Kelly-Goerss Compass system served as the stereotactic platform.
Main Results:
- PET-[18F]-fluorodeoxyglucose (FDG) imaging provided clinically significant information.
- PET-FDG successfully directed biopsy efforts in cases where CT and MRI were inconclusive or misleading.
- The integration of PET-FDG images into routine stereotactic surgery was demonstrated.
Conclusions:
- PET-FDG imaging can enhance the accuracy of stereotactic biopsies for intracranial mass lesions.
- PET-FDG offers valuable metabolic information that complements anatomical imaging (CT/MRI).
- PET-FDG can be effectively incorporated into image-directed stereotactic surgical procedures.